Table 2.
Overview of human trials of HER2 targeting affibodies in breast cancer patients. Status of April 2020
| Affibody | Radioisotope | Diagnostic/therapy | Trial no. | Phase | Patients | First posted | Reference |
|---|---|---|---|---|---|---|---|
| ABY-002 | 68Ga | PET | EudraCT 2007 002530 11 | Pilot study | 3 | 07/2007 | [102] |
| 111In | SPECT | ||||||
| ABY-025 | 111In | SPECT | NCT01216033 | I/II | 7 | 10/2010 | [103] |
| 68Ga | PET | NCT02095210 | I | 8 | 03/2014 | [104] | |
| NCT01858116 | I/II | 16 | 05/2013 | [105] | |||
| NCT03655353 | II/III | 120 | 08/2018 | Nonpublished | |||
| ABH2 | 99mTc | SPECT | NCT03546478 | I | 32 | 06/2018 | [106] |
| HPArk2 | NCT04267900 | I | 30 | 02/2020 | Nonpublished | ||
| GE-226 | 18F | PET | NCT03827317 | Not applicable | 16 | 02/2019 | Nonpublished |